Do analysts rate LIMN or PPBT?

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, LIMN or PPBT?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is LIMN or PPBT more profitable?

Liminatus Pharma's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Purple Biotech N/A -123.63% -98.72%

Do analysts prefer APM or PPBT?

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Purple Biotech is more favorable than Aptorum Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, APM or PPBT?

Aptorum Group has higher revenue and earnings than Purple Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 9.86 -$1.36M N/A N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is APM or PPBT more profitable?

Aptorum Group's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Purple Biotech N/A -123.63% -98.72%

Do analysts prefer INM or PPBT?

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend AKAN or PPBT?

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, AKAN or PPBT?

Purple Biotech has lower revenue, but higher earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 17.01 -$45.65M N/A N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is AKAN or PPBT more profitable?

Akanda's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A Purple Biotech N/A -123.63% -98.72%

Do analysts rate PPBT or GNPX?

Purple Biotech presently has a consensus target price of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Purple Biotech is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PPBT or GNPX?

Genprex is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is PPBT or GNPX more profitable?

Purple Biotech's return on equity of -123.63% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% Genprex N/A -247.32% -176.73%

Purple Biotech (PPBT) Competitors

$1.40 -0.06 (-3.79%)

As of 12:59 PM Eastern

Compare

PPBT vs. LIMN, APM, INM, AKAN, and GNPX

Should you buy Purple Biotech stock or one of its competitors? MarketBeat compares Purple Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Purple Biotech include Liminatus Pharma (LIMN), Aptorum Group (APM), InMed Pharmaceuticals (INM), Akanda (AKAN), and Genprex (GNPX). These companies are all part of the "pharmaceutical products" industry.

How does Purple Biotech compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Purple Biotech (NASDAQ:PPBT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.6% of Purple Biotech shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Liminatus Pharma has a beta of 5.62, indicating that its stock price is 462% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Purple Biotech	N/A	-123.63%	-98.72%

In the previous week, Liminatus Pharma's average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Purple Biotech	Neutral

Liminatus Pharma is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Summary

Purple Biotech beats Liminatus Pharma on 6 of the 11 factors compared between the two stocks.

How does Purple Biotech compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Aptorum Group's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Purple Biotech	N/A	-123.63%	-98.72%

Aptorum Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Purple Biotech is more favorable than Aptorum Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aptorum Group has higher revenue and earnings than Purple Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	9.86	-$1.36M	N/A	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

In the previous week, Aptorum Group had 3 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Aptorum Group and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.00 beat Aptorum Group's score of -0.67 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptorum Group	Negative
Purple Biotech	Neutral

Summary

Aptorum Group and Purple Biotech tied by winning 6 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

InMed Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

InMed Pharmaceuticals has higher revenue and earnings than Purple Biotech. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.02	-$8.16M	-$2.89	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Purple Biotech has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Purple Biotech	N/A	-123.63%	-98.72%

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Purple Biotech	Neutral

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

InMed Pharmaceuticals beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Akanda?

Akanda (NASDAQ:AKAN) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Akanda's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Purple Biotech	N/A	-123.63%	-98.72%

Purple Biotech has lower revenue, but higher earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	17.01	-$45.65M	N/A	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

1.0% of Akanda shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 20.4% of Akanda shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Akanda has a beta of 14.06, meaning that its stock price is 1,306% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Akanda's average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Overall Sentiment
Akanda	Neutral
Purple Biotech	Neutral

Summary

Akanda and Purple Biotech tied by winning 5 of the 10 factors compared between the two stocks.

How does Purple Biotech compare to Genprex?

Purple Biotech (NASDAQ:PPBT) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Purple Biotech presently has a consensus target price of $30.00, suggesting a potential upside of 2,050.54%. Given Purple Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Purple Biotech is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Genprex had 3 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Genprex and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.00 beat Genprex's score of -0.67 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Purple Biotech	Neutral
Genprex	Negative

Purple Biotech's return on equity of -123.63% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Genprex	N/A	-247.32%	-176.73%

Purple Biotech has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Genprex has a beta of -0.92, suggesting that its stock price is 192% less volatile than the broader market.

Genprex is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Summary

Purple Biotech beats Genprex on 9 of the 13 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30M	$3.65B	$6.80B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.07	20.62	27.03	24.19
Price / Sales	N/A	311.45	515.69	92.93
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.13	8.13	10.67	6.24
Net Income	-$26.39M	$23.81M	$3.59B	$331.42M
7 Day Performance	-1.06%	-1.31%	-0.60%	-1.18%
1 Month Performance	-17.94%	2.40%	1.63%	-1.34%
1 Year Performance	-94.98%	44.89%	25.09%	18.73%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	2.9897 of 5 stars	$1.40 -3.8%	$30.00 +2,050.5%	-94.4%	$1.30M	N/A	N/A	20
LIMN Liminatus Pharma	0.2589 of 5 stars	$0.10 -4.5%	N/A	-97.9%	$5.24M	N/A	N/A	N/A	Positive News Gap Down
APM Aptorum Group	0.8975 of 5 stars	$0.81 +0.6%	N/A	-95.9%	$5.17M	$430K	N/A	30
INM InMed Pharmaceuticals	0.9446 of 5 stars	$1.56 -0.6%	N/A	-43.1%	$5.16M	$4.94M	N/A	10	Gap Down
AKAN Akanda	0.7629 of 5 stars	$9.48 -1.0%	N/A	-89.7%	$5.12M	$260K	N/A	110	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. LIMN, APM, INM, AKAN, and GNPX

How does Purple Biotech compare to Liminatus Pharma?

Summary

How does Purple Biotech compare to Aptorum Group?

Summary

How does Purple Biotech compare to InMed Pharmaceuticals?

Summary

How does Purple Biotech compare to Akanda?

Summary

How does Purple Biotech compare to Genprex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. LIMN, APM, INM, AKAN, and GNPX

How does Purple Biotech compare to Liminatus Pharma?

Do analysts rate LIMN or PPBT?

Do insiders & institutionals believe in LIMN or PPBT?

Which has more risk & volatility, LIMN or PPBT?

Is LIMN or PPBT more profitable?

Does the media prefer LIMN or PPBT?

Which has higher valuation & earnings, LIMN or PPBT?

Summary

How does Purple Biotech compare to Aptorum Group?

Is APM or PPBT more profitable?

Which has more risk & volatility, APM or PPBT?

Do analysts prefer APM or PPBT?

Do insiders and institutionals have more ownership in APM or PPBT?

Which has better earnings & valuation, APM or PPBT?

Does the media favor APM or PPBT?

Summary

How does Purple Biotech compare to InMed Pharmaceuticals?

Which has more volatility and risk, INM or PPBT?

Which has stronger valuation and earnings, INM or PPBT?

Is INM or PPBT more profitable?

Do analysts prefer INM or PPBT?

Does the media prefer INM or PPBT?

Do insiders & institutionals hold more shares of INM or PPBT?

Summary

How does Purple Biotech compare to Akanda?

Do analysts recommend AKAN or PPBT?

Is AKAN or PPBT more profitable?

Which has higher valuation and earnings, AKAN or PPBT?

Do institutionals and insiders hold more shares of AKAN or PPBT?

Which has more risk & volatility, AKAN or PPBT?

Does the media favor AKAN or PPBT?

Summary

How does Purple Biotech compare to Genprex?

Do analysts rate PPBT or GNPX?

Do insiders & institutionals have more ownership in PPBT or GNPX?

Does the media favor PPBT or GNPX?

Is PPBT or GNPX more profitable?

Which has more volatility and risk, PPBT or GNPX?

Which has preferable earnings and valuation, PPBT or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools